Biology versus pharmacology in drug resistance (review)

Oncology Reports

Volumn 4, Issue 1 SUPPL., 1997, Pages 207-210

  D'Alessandro, N ^a   Flugy, A ^a   Borsellino, N ^a   Travali, S ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Cytokines; Drug resistance; Multidrug transporters; Oncogenes

Indexed keywords

ACETYLCYSTEINE; AMSACRINE; CALPHOSTIN C; DACTINOMYCIN; DOXORUBICIN; GENISTEIN; GROWTH FACTOR; INTERLEUKIN 6; MITOXANTRONE; N(G) METHYLARGININE; STAUROSPORINE; TUMOR NECROSIS FACTOR ALPHA; WORTMANNIN;

APOPTOSIS; CANCER CHEMOTHERAPY; CONFERENCE PAPER; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL;

EID: 0031037682     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Pinedo HM and Giaccone G: P-glycoprotein - a marker of cancer cell behavior. N Engl J Med 333: 1417-1419, 1995.
2. De Isabella P, Capranico G and Zunino F: The role of topoisomerase II in drug resistance. Life Sci 48: 2195-2205, 1991.
3. Tsai CM, Chang KT, Perng RP, Mitsudomi T, Chen MH, Kadoyama C and Gazdar AF: Correlation of intrinsic chemoresistance of non-small cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 85: 897-901, 1993.
4. Scanlon KJ, Kashani-Sabet M, Tone T and Funato T: Cisplatin resistance in human cancers. Pharmacol Ther 52: 385-406, 1991.
5. Niimi S, Nakagawa K and Yokota J: Resistance to anticancer drugs in NIH3T3 cells with c-myc and/or c-H-ras genes. Br J Cancer 63: 237-241, 1991.
6. new expressing non-small cell lung cancer cells. Cancer Res 56: 1068-1074, 1996.
7. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB and Slamon DJ: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9: 1829-1838, 1994.
8. Soma MR, Baetta R, De Renzis MR, Mazzini G, Devegna C, Magrassi L, Pezzotta S, Paoletti R and Fumagalli R: In vivo enhanced antitumor activity of carmustine by simvastatin. Cancer Res 55: 597-602, 1995.
9. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994.
10. Rush Y, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M and Dmitrovsky E: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55: 5038-5042, 1995.
11. Righetti SC, Delia Torre G, Pilotti S, Menard S, Ottpne F, Colnaghi MI, Pierotti MA, Lavarino C, Comarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G and Zunino S: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689-693, 1996.
12. Chresta CM, Masters JRW and Hickman JA: Hypersensitivity of human tcsticular tumors to etoposide-induced apoptosis is associated with functional p53 and a high bax:bcl-2 ratio. Cancer Res 56: 1834-1841, 1996.
13. Miyashita T and Ree JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157, 1993.
14. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S and Reed JC: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoman. Cancer Res 55: 4471-4478, 1995.
15. Mercola D and Cohen JS: Antisense approaches to cancer gene therapy. Cancer Gene Ther 2: 47-59, 1995.
16. Lotem J and Sachs L: Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor ßl and cancer chemotherapy compounds in myeloid leukemic cells. Blood 80: 1750-1757, 1992.
17. Sell C, Baserga R and Rubin R: Insulin-like growth factor (IGF-1) and the IGF-1 receptor prevent etoposide-induced apoptosis. Cancer Res 55: 303-306, 1995.
18. Borsellino N, Belldegrun A and Bonavida B: Endogenous interleukin-6 is a resistance factor for cis-diamminedichloro-platinum and etoposide-mediated cytotoxicity of human prostate cancer cell lines. Cancer Res 55: 4633-4639, 1995.
19. Nakajima K, Matsuda T, Fujitani Y, Kojima H, Yamanaka Y, Nakae K, Takeda T and Hirano T: Signal transduction through IL-6 receptor; involvement of multiple protein kinases, Stat factors and a novel H7-sensitive pathway. In: Interleukin-6-Type Cytokines. Mackiewicz A, Koj A and Sehgal PB (eds). Vol. 762. Ann NY Acad Sci, NY, pp55-70, 1995.
20. Savino R, Ciapponi L, Lahm A, Demartis A, Cabibbp A, Toniatti C, Delmastro P, Altamura S and Ciliberto G: Rational design of a receptor super-antagonist of human interleukin-6. EMBO J 13: 5863-5870, 1994.
21. Morimoto H, Yonehara S and Bonavida B: Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res 53: 2591-2596, 1993.
22. Leonardi V, Borsellino N, Crescimanno M, Flandina C, Flugy A and D'Alessandro N: Combinative growth inhibitory effects of interferon-α and doxorubicin on multidrug resistant cell lines. Oncol Rep 1: 161-164, 1994.
23. Flugy A, Borsellino N and D'Alessandro N: TNF-induced apoptosis in multidrug resistant Friend erythroleukemia is not influenced by the P-glycoprotein and glutathione status of the cell line. Oncol Res 7: 559-564, 1995.
24. Fuchs EJ, Bedi A, Jones RJ and Hess AD: Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res 55: 463-466, 1995.
25. D'Alessandro N, Borsellino N, Leonardi V and Crescimanno M: Immunological implications of tumour drug resistance. Forum 4: 124-143, 1994.
26. Farhood H, Gao X, Son K, Yang YY, Lazo JS, Huang L, Barsoum J, Bottega R and Epand RM: Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. In: Gene Therapy for Neoplastic Diseases. Huber BE and Lazo JS (eds). Vol. 716. Ann NY Acad Sci, NY, pp23-25, 1994.
27. D'Alessandro N and Borsellino N: In vivo effects of tumor necrosis factor-α or flavone acetic acid in combination with doxorubicin on multidrug-resistant B16 melanoma. Anti-Cancer Drugs 7: 281-287, 1996.
28. Chin KV, Ueda K, Pastan I and Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by Ras and P53: Science 255: 459-462, 1991.
29. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM and Norris MD: Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54: 5036-5040, 1994.
30. Scotlandi K, Serra M, Nicoletti G, Vaccari M, Manara MC, Nini G, Landuzzi L, Colacci A, Bacci G, Bertoni F, Picci P, Campanacci M and Baldini N: Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 56: 2237-2462, 1996.